Institutional shares held 85.9 Million
1.55M calls
1.37M puts
Total value of holdings $5.28B
$95.5M calls
$84.2M puts
Market Cap $5.33B
87,567,904 Shares Out.
Institutional ownership 98.06%
# of Institutions 521


Latest Institutional Activity in SRPT

Top Purchases

Q1 2025
Assenagon Asset Management S.A. Shares Held: 713K ($43.4M)
Q1 2025
Sovran Advisors, LLC Shares Held: 57.5K ($3.5M)
Q1 2025
Imc Chicago, LLC Shares Held: 18K ($1.09M)
Q1 2025
Peregrine Capital Management LLC Shares Held: 68.9K ($4.19M)
Q1 2025
Janney Montgomery Scott LLC Shares Held: 12.9K ($783K)

Top Sells

Q1 2025
Banque Pictet & Cie Sa Shares Held: 3.24K ($197K)
Q1 2025
Gamma Investing LLC Shares Held: 640 ($38.9K)
Q1 2025
Principal Financial Group Inc Shares Held: 245K ($14.9M)
Q1 2025
Allspring Global Investments Holdings, LLC Shares Held: 50.5K ($3.07M)
Q1 2025
Braun Stacey Associates Inc Shares Held: 65.9K ($4.01M)

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at SRPT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
295K Shares
From 22 Insiders
Grant, award, or other acquisition 65.3K shares
Exercise of conversion of derivative security 192K shares
Open market or private purchase 37K shares
Sell / Disposition
154K Shares
From 15 Insiders
Bona fide gift 996 shares
Open market or private sale 75K shares
Payment of exercise price or tax liability 77.9K shares

Track Institutional and Insider Activities on SRPT

Follow Sarepta Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT